the stock price has definitely been slipping. Although there is anticipation of the approvals, we still need sales and because of the relatively low margins, we need lots of sales to get to profitability.
Sales performance after the approvals will be crucial. If approvals are late, actual sales are going to get pushed into 2019. But we still have a month in Q1 and 4 month before Q2 is done and if the products are good, there should be growing sales in Canada.
The US approval remains the big ticket. I don't think the stock will get that big a pop from Canadian approval, due to the market size. Hopefully we'll find out about that pretty quick.
Bobwins
News 
Market Data 
Discover 
